HTEC to Support Digital Telco Enabler Telness Tech in Platform Software Development
17.9.2024 18:31:00 CEST | Business Wire | Press release
Telness Tech, a fast-growing international software company founded in Sweden, and HTEC, a global end-to-end digital product development and engineering services company, are pleased to announce their work on Telness Tech’s innovative platform, which will support the company’s ongoing expansion into new markets, like the US.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240917678716/en/
In this partnership, HTEC will support Telness Tech by providing additional engineering expertise for the new platform’s deployment, customization, and user migration from legacy platforms. HTEC will also assist in the development of business-to-consumer (B2C) applications and various network integrations, including building an abstraction layer for easier integrations. (Graphic: Business Wire)
The platform’s proprietary software is a cloud-based, end-to-end solution for mobile virtual network operators (MVNOs) that offers comprehensive operations and business support system (OSS/BSS) capabilities. It streamlines and automates the customer journey, deploying quickly and remotely without the need for traditional telco infrastructure or legacy IT systems. The platform has already helped Telness Tech clients boost customer ratings in Europe.
In the partnership, HTEC will support Telness Tech by providing additional engineering expertise for the new platform’s deployment, customization, and user migration from legacy platforms. HTEC will also assist in the development of business-to-consumer (B2C) applications and various network integrations, including building an abstraction layer for easier integrations.
Commenting on the collaboration, HTEC’s Director of Engineering & Delivery Bojan Šukalo said:
“Recent tech innovations have transformed how we communicate, but many in the telco industry still use traditional infrastructure. With HTEC’s technical expertise and engineering capacity, we’re perfectly positioned to support the industry’s digital transformation and aligned with Telness Tech to steer the industry forward.”
Founder and COO of Telness Tech, Jonas Cedenwing, highlighted the value of HTEC’s support in this expansion:
“With high demand for our software across the globe, partnering with HTEC ensures that our clients’ platform demands and transitions remain smooth and streamlined, enabling us to continue our high expansion rate without compromising quality.”
About Telness Tech
Founded in Sweden with offices in the US, Telness Tech provides everything needed to launch or run a fully automated mobile operator. The company’s end-to-end BSS/OSS solutions streamline customer journeys, provisioning, and porting — necessary functions to run a digital mobile operator. As a result, satisfied clients drastically reduce operational costs.
About HTEC
HTEC Group Inc. is a global premium technology services firm powering the technological evolution of the world’s most impactful organizations—from disruptive startups to the Fortune 500. HTEC combines deep engineering expertise with remarkable creativity, enabling its customers to innovate, design, and develop disruptive technologies and new digital solutions across different industries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917678716/en/
Contacts
HTEC Media Relations: media@htecgroup.com
HTEC Media Relations: media@htecgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom